The Drug Development Global Series
Our Drug Modalities and Manufacturing Global Event Series is dedicated to supporting the development of novel pharmaceutical modalities – antibody constructs, fusion proteins, small molecules - and integrated platforms which can deliver clinical and commercial-scale API production across the pharma/biotech spectrum.
Through an array of niche conferences, this series brings together a global audience and global line-up of executive speakers exploring next generation of drug candidates, including novel peptides, oligonucleotides, and molecular conjugates, which are create therapeutic opportunities and can address challenging disease relevant targets and biological processes. As advanced drug modalities open avenues in drug discovery, we will be uncovering the new set of challenges for innovators striving to manufacture at sufficient scale to simultaneously meet market demand, high-quality standards, cGMP processes, and scalability for acceptable ROI.
WHAT WE DO
Anchored by our flagship Summit series, we also provide additional opportunities for our Drug Modalities community to network and learn through our webinars, virtual events, roundtables and Start-Up Showcases.
-
Live Summits
Our in-person, industry-led events bring the various drug modalities and manufacturing technology communities together.
-
Webinars
Topic specific deep dives bring together hundreds of our global network together to learn from key partners and thought leaders.
-
Start-Up Showcases
Run as part of our flagship events, these showcases provide a platform for leading innovators to pitch their ideas to leading investors and strategic partners
Drug Development Series Calendar
Filter by:
Events Calendar
= Flagship Event
= Paid Event
Our Network
Forging an accessible and exclusive community to accelerate new clinical-validated drug modalities to patients at commercial-scale.
Our mission is to provide a global researchers and manufacturers a dedicated network for open collaboration to drive innovation and investment at the leading edge of drug development.
